+ bendamustine + rituximab, ibrutinib vs temsirolimus, and ibrutinib vs rituximab were included in the analysis. The incidence of treatment discontinuation due to adverse events was 9.30% in the ibrutinib group vs 13.13% in the control arm. The relative risk (RR
Search Results
Meily Arevalo, Myo H. Zaw, Anita Sultan, Sriman Swarup, Nay N. Yee, Wai L. Thein, Myet M. Zin, Nusrat Jahan, and Kyaw Z. Thein
Miguel Quirch, Sriman Swarup, Anita Sultan, Wai L. Thein, Zayar M. Oo, Nyein H. Yu, Myo H. Zaw, Donald P. Quick, and Kyaw Z. Thein
(I) vs ofatumumab, I vs chlorambucil, I+ bendamustine (B) + rituximab (R) vs placebo + B+ R, I vs temsirolimus and I vs R were included in the analysis. The relative risks (RR) of all-grade side effects were as follows: anemia, 0.812 (95% CI: 0
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
, interferon alfa (IFN-α) and interleukin (IL)-2 comprised the available systemic treatment options. Since then, 7 new agents have been approved by the FDA for treatment of RCC: sorafenib, sunitinib, temsirolimus, bevacizumab, everolimus, pazopanib, and
overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients With Advanced Gynecological Malignancies Principal Investigator
scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Principal
scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
, Vanderbilt-Ingram Cancer Center • 800-811-8480 ClinicalTrials.gov Identifier: NCT00983268 A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Principal Investigator
Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors Principal Investigator: Ira Dunkel, MD Condition: Pediatric solid tumors Institution: Memorial Sloan-Kettering Cancer Center This study is testing the safety and
scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas
